Identifying and Targeting Angiogenesis-related microRNAs in Ovarian Cancer


Authors: X. Chen, L.S. Mangala, L. Mooberry, E. Bayraktar, S.K. Dasari, S. Ma, C. Ivan, K.A. Court, C. Rodriguez-Aguayo, R. Bayraktar, S. Raut, N. Sabnis, X. Kong, X. yang, G. Lopez-Berestein, A.G. Lacko, and A. K. Sood

Journal: Oncogene

DOI: 10.1038/s41388-019-0862-y

Publication - Abstract

July 09, 2019

Abstract

Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein–nanoparticles (rHDL–NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Summary

Effective Lipidoid Nanoparticle Delivery In Vivo of siRNA Targeting Kappa Light Chain Production in a Murine Xenograft Model

X. Ma, P. Zhou, A. Kugelmass, D. Toskic, M. Warner, L.X. Lee, T. Fogaren, M. Wang, Y. Li, L. Yang, Q. Xu and R. Comenzo

Researchers at Tufts University have recently reported a proof of concept for siRNA-LNP treatment for AL amyloidosis - a bone marrow disorder where Immunoglobulin (Ig) light chains (LC) misfold into amyloids that deposit in a variety of other tissues where they cause disfunction ...
Read More


Publication - Summary

Yizhou Dong’s group at Ohio State University have published a paper describing a small molecule/mRNA lipid nanoparticle combination therapy for triple negative breast cancer (TNBC). TNBC represents about 15% of all breast cancers. The Dong lab’s approach involved deli...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.